Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Multidisciplinary Management for the Treatment of DTC

January 18th 2021

Approaching Treatment of Low-Volume DTC

January 18th 2021

Understanding Sequencing and What to Look for in DTC

January 18th 2021

Roles and Communication in Treatment in DTC

January 11th 2021

Management of DTC in Clinical Practice

January 11th 2021

NICE Rejects Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

January 8th 2021

January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy.

Discussing Iodine-Refractory DTC With Patients

January 4th 2021

Clinical Scenarios to Consider for RAI-Refractory DTC

January 4th 2021

Lindau on Leading Successful Surgical Fellowships

December 31st 2020

In our exclusive interview, Robert Lindau, III, MD, discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.

SGX942 Shows Meaningful Reduction in Oral Mucositis in Head and Neck Cancer, But Not Statistically Significant

December 23rd 2020

December 23, 2020 — Although SGX942 was found to induce clinically meaningful reductions in severe oral mucositis vs placebo in patients with head and neck cancer, the benefit failed to reach statistical significance, thus missing the primary end point of the phase 3 DOM-INNATE study.

Cabozantinib Significantly Improves PFS in Previously Treated, Radioiodine-Refractory Differentiated Thyroid Cancer

December 21st 2020

December 21, 2020 - Cabozantinib was found to significantly improve progression-free survival compared with placebo in patients with dedifferentiated thyroid cancer who are refractory to radioiodine and have progressed following up to 2 prior VEGF-targeted treatments.

Thyrotropin Suppression as DTC Treatment Option

December 21st 2020

Role of Radioiodine Treatment in DTC

December 21st 2020

DTC: Histological Subtypes and Tumor Differentiation

December 14th 2020

Differentiated Thyroid Cancer: Increasing Incidence

December 14th 2020

FDA Approves Pralsetinib for RET+ Thyroid Cancers

December 1st 2020

December 1, 2020 - The FDA has approved pralsetinib for the treatment of select patients with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13th 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13th 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer

November 12th 2020

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

x